Double Blind, Placebo Controlled, Escalating Single-dose, Pilot Study to Assess the Safety of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA).

Trial Profile

Double Blind, Placebo Controlled, Escalating Single-dose, Pilot Study to Assess the Safety of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs THR 18 (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2016 This trial was completed in Austria (end date: 2012-07-17), according to European Clinical Trials Database.
    • 26 May 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005317-37).
    • 18 Jan 2012 Patient enrolment is underway in Israel, with additional sites expected in India, Europe (Spain, Austria, Germany) and the USA, according to a Hadasit Bio-Holdings media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top